Confounder-controlled designs resolve the egg–CVD question faster than more cohorts
Statement
The disagreement is resolved more efficiently by better-identified designs than by additional observational cohorts that inherit the same confounding structure. The highest-leverage moves are individual-participant-data reanalysis with harmonized confounder adjustment across cohorts, pre-registered analysis plans that fix the adjustment set in advance, and — where feasible — randomized trials on hard cardiovascular endpoints rather than on serum-lipid surrogates.
Provenance
Sources
- Zhuang et al. — Egg/cholesterol, serum cholesterol, and mortality; updated meta-analysis (Circulation)https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057642Updated meta-analysis; associations vary by population and by adjustment set, underscoring residual confounding and effect-heterogeneity as the binding constraints on inference.
- Sabaté et al. dose-response meta-analysis of egg consumption and CVD (Eur J Nutrition)https://link.springer.com/article/10.1007/s00394-020-02345-7Dose-response meta-analysis of prospective cohorts; up to one egg/day not associated with (and up to ~six/week inversely associated with) CVD — a result sensitive to the confounder-adjustment model.
Causal links
Confounder-controlled, pre-registered designs (individual-participant reanalysis with harmonized covariates, or an RCT on hard endpoints) shrink the residual-confounding uncertainty that keeps the egg–CVD claim contested, moving it toward resolution.
Validated against recovery biomarkers, the instruments these cohorts run on correlate with true intake at roughly 0.21 for energy and 0.29 for protein, and under-report energy by about 28 percent in a way BMI predicts. An exposure measured that badly attenuates the association toward the null and leaves its magnitude at the mercy of the adjustment set, so more cohorts built on the same questionnaires accumulate precision around a moving estimate rather than converging on one. That is the reason to believe ECL1's central claim, and the relation is evidential rather than causal: measurement error does not make better-identified designs work, it is what makes the alternative fail. Scoped to that limb — ECL1 also recommends randomized trials on hard endpoints, which this evidence does not reach.